A peptide supplier can publish a polished purity claim, a discount code, and a product photo without proving what is in the vial. A proper COA evidence review starts where marketing stops: with the underlying laboratory documentation. The question is not whether a supplier has uploaded a PDF. The question is whether that document credibly connects an independently tested sample to the specific product being offered.
For research-use-only buyers, this distinction is practical. A Certificate of Analysis can support a quality assessment, but only when it is current, legible, product-specific, and issued by a laboratory that is independent of the seller. Vendors that cannot document product contents should not receive the same trust as vendors that can.
What a COA is supposed to prove
A Certificate of Analysis is a testing record for a specific sample. In the peptide market, the most useful COAs address three baseline questions: Is the compound the stated identity? Is it present at an acceptable purity level? Does the vial contain the represented amount?
Those questions require different kinds of evidence. Identity testing commonly relies on methods such as mass spectrometry, which evaluates molecular mass and helps determine whether the tested material matches the claimed compound. Purity testing often uses high-performance liquid chromatography, or HPLC, to identify the proportion of the sample associated with the target analyte versus detectable impurities. Net content or conformity testing evaluates whether the actual material amount aligns with the label claim.
A report that shows only one of these categories is incomplete. A high HPLC purity result, for example, does not by itself confirm that the peak belongs to the peptide named on the label. Likewise, an identity result cannot tell a buyer whether the sample contains substantial impurities or whether a 10 mg vial actually contains its stated net content.
COA evidence review: the checks that matter
The best review is not based on a single percentage at the top of a report. It examines the chain of evidence from sample to product. Start by looking for a clear product or sample identifier. The name on the COA should correspond to the compound sold, and the lot or batch number should match the product lot when that information is available.
Dates matter just as much. A report from years ago may demonstrate that a supplier tested something at one point, but it does not establish that the current inventory meets the same standard. Peptide suppliers should be able to provide recent documentation for active product lots, not rely indefinitely on a legacy report.
The laboratory must also be identifiable. A credible COA names the testing laboratory and includes enough information to distinguish it from the vendor. A document branded only with the seller's own logo, or one that lists no laboratory, analyst, methodology, or report number, is not independent evidence. It is an internal claim presented in the format of a test result.
Review the analytical method rather than assuming every document labeled "COA" is comparable. HPLC chromatograms should be readable, with retention time, peak area, and a stated purity result. Identity testing should state the method used and provide a result that supports the claimed molecular mass. Net-content testing should identify what was measured and how the result relates to the label claim.
A useful report also preserves enough context for verification: sample receipt or analysis dates, instrument or method references, analyst authorization, and a report or certificate number. Not every laboratory formats documents identically, but missing traceability is a meaningful limitation.
Why purity percentages can mislead
A headline such as "99% purity" sounds decisive. It is not decisive without context. Purity is a measurement result tied to a method, a sample, and a defined calculation. It does not automatically establish identity, fill weight, sterility, or suitability for any use.
Chromatographic purity can also be expressed in different ways. Area-percent purity is common, but it reflects the relative signal detected under stated analytical conditions. It is not a substitute for quantitative assay or net-content confirmation. A sample can show a dominant chromatographic peak and still fail to support the amount printed on a vial label.
This is why a vendor's claimed purity threshold should be read alongside the full report. Ask whether the test identifies the material, whether the chromatogram is attached, whether the sample is tied to a lot, and whether testing is recent. If the seller provides only a cropped image of a result or a generic statement that products are "third-party tested," there is no meaningful basis for comparison.
Higher testing tiers answer different risks
Identity, purity, and net content form the baseline. Depending on the product format and research context, additional testing can materially improve the evidence picture. These tests should not be confused with one another.
Sterility testing evaluates whether viable microorganisms are detected under the test conditions. Endotoxin testing evaluates bacterial endotoxin, which is a separate concern and can be relevant even when a sterility test does not detect viable organisms. Heavy metals testing examines specified elemental contaminants. Conformity testing may assess whether product characteristics match defined specifications, including fill or labeling-related requirements.
A vendor that offers these higher testing tiers is providing more than a generic purity claim. Still, the details control the value. A sterility statement without method, date, sample identifier, or laboratory attribution is weak evidence. Heavy metals results should identify the elements tested and the limits used. Endotoxin reports should state the measured result and applicable specification rather than simply saying "passed."
Higher-tier testing is not a license for overstatement. Research-use-only materials are not approved medicines, and a COA does not establish safety, efficacy, or fitness for human use. It documents limited analytical findings for a tested sample. That boundary is part of responsible evidence review.
Red flags that should lower confidence
Some deficiencies are more serious than others, but certain patterns should immediately reduce confidence in a supplier's quality claims:
A COA has no laboratory name, report number, test date, or sample identifier.
The document does not identify a method for purity or identity testing.
The batch number is absent or does not match the product being sold.
One generic report is used across multiple compounds, strengths, or years of inventory.
Results appear as typed claims without raw data, chromatograms, spectra, or clear analytical context.
The vendor refuses to provide current lot documentation after being asked.
None of these signs automatically proves fraud. A laboratory may use a simplified report format, and a supplier may have an administrative explanation for a mismatch. But evidence review is about qualification, not inventing excuses for missing records. When documentation cannot establish what was tested, uncertainty belongs with the vendor, not the buyer.
A practical way to compare suppliers
When comparing peptide suppliers, begin with the same baseline for every vendor. Confirm that current independent COAs exist for the compounds offered. Then assess whether each report supports identity, purity, and net content. After that, compare higher-tier evidence such as sterility, endotoxin, heavy metals, and conformity testing.
This approach prevents a common mistake: giving a vendor credit for one attractive test result while overlooking missing categories that matter. It also keeps price in its proper place. A coupon may improve the cost of a documented product, but a discount cannot compensate for unverified contents. Community-verified deal information is useful only after supplier qualification is established.
RUO Codes applies this evidence-first logic to supplier evaluation. Third-party testing documentation is the entry point, not a premium feature reserved for a few products. Buyers can then compare which vendors go beyond baseline testing and which ones rely on claims that cannot be independently assessed.
When a COA needs follow-up
A COA does not need to be flawless to be useful, but unclear records deserve direct questions. Ask the vendor whether the report is tied to the current lot, whether the named laboratory performed the testing independently, and whether supporting chromatograms, spectra, or net-content results are available. A qualified supplier should be able to answer plainly.
The strongest vendors make review easier because their records are organized, current, and connected to actual inventory. That is not administrative polish. It is accountability. Treat every COA as evidence to be evaluated, not as a badge to be accepted, and let the quality of the documentation determine how much confidence a supplier earns.